Permethrin foam

Drug Profile

Permethrin foam

Alternative Names: PerFoamFive; PerFoamOne; Permethrin foam - Foamix

Latest Information Update: 27 May 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Foamix
  • Class Antiparasitics; Pyrethrins; Small molecules
  • Mechanism of Action Sodium channel agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Pediculosis; Scabies

Most Recent Events

  • 02 May 2013 Clinical development is ongoing in Israel
  • 22 Sep 2010 Taro Pharmaceutical Industries has been acquired by Sun Pharmaceutical Industries
  • 07 Sep 2009 Clinical trials in Pediculosis in Israel (Topical, 5% foam)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top